- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus (T2DM)
- Meeting Date: November 2022
- Public Summary Document (PSD) October 2022 PBAC Out-of-Session - (PDF 347KB)
- Public Summary Document (PSD) October 2022 PBAC Out-of-Session - (Word 220KB)
Dulaglutide – November 2022
Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen (s19A); Trulicity® (Netherlands)
Last updated
8 July 2025